Talquetamab (JNJ-64407564) is a bispecific monoclonal antibody binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells.
| SparkCures ID | 306 |
|---|---|
| Developed By | Janssen Research & Development |
| Generic Name | Talquetamab |
| Additional Names | JNJ-64407564 |
| Treatment Classifications | |
| Treatment Targets |
|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.